Clinical Edge Journal Scan

Gastric cancer: What is the optimal surgical strategy in the elderly?

Key clinical point: In older patients with potentially resectable gastric cancer, gastrectomy vs. conservative treatment may improve survival. The minimally invasive approach has fewer complications and extended lymphadenectomy may have survival benefit.

Major finding: Gastrectomy vs. conservative treatment improved overall survival in all six studies included in the analysis, but study quality was low and meta-analysis was not feasible. Minimally invasive vs. open gastrectomy was associated with fewer complications (pooled risk ratio 0.71; P = .005) and similar OS ( P = .58). Extended vs. limited lymphadenectomy prolonged OS or cancer-specific survival in two cohort studies, with similar complication rates.

Study details: This systematic review of 31 studies included patients aged ≥ 70 years with potentially resectable stage I-III gastric cancer.

Disclosures: This study had no sponsors. The authors declared no conflicts of interest.

Source: Argillander TE et al. Outcomes of surgical treatment of non-metastatic gastric cancer in patients aged 70 and older: A systematic review and meta-analysis. Eur J Surg Oncol. 2022 (May 16). Doi: 10.1016/j.ejso.2022.05.003

Recommended Reading

Heavy drinking associated with increased risk for EOCRC irrespective of genetic risk
MDedge Hematology and Oncology
Refractory metastatic CRC: Raltitrexed plus S-1 betters regorafenib in prolonging survival
MDedge Hematology and Oncology
CRC with synchronous liver metastases: Outcomes of simultaneous laparoscopic vs. hybrid and open resection
MDedge Hematology and Oncology
Does high consumption of nuts and legumes protect against CRC?
MDedge Hematology and Oncology
Obesity and metabolic syndrome at younger ages may increase earlier-onset CRC risk
MDedge Hematology and Oncology
Multi-agent vs. single-agent adjuvant chemotherapy in elderly patients with stage III colon cancer
MDedge Hematology and Oncology
Advanced gastric cancer: Ramucirumab-irinotecan combo fails phase 2
MDedge Hematology and Oncology
Gastric cancer: Tumor mutational burden and outcomes with pembrolizumab
MDedge Hematology and Oncology
Is there a link between tea consumption and gastric cancer?
MDedge Hematology and Oncology
Metastatic gastric cancer: CD163+ macrophage infiltration is a prognostic biomarker
MDedge Hematology and Oncology